Baird Initiates Coverage On Inari Medical with Outperform Rating, Announces Price Target of $79
Portfolio Pulse from richadhand@benzinga.com
Baird analyst David Rescott has initiated coverage on Inari Medical (NASDAQ:NARI) with an Outperform rating and a price target of $79.
July 19, 2023 | 8:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inari Medical has received an Outperform rating from Baird with a price target of $79.
The Outperform rating from Baird indicates a positive outlook for Inari Medical. The price target of $79 suggests that Baird expects the stock to rise in the short term. This could potentially lead to an increase in the stock's price as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100